Every 424B that Ibio (IBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBIO filings page.
iBio, Inc. filed a prospectus supplement updating a resale registration that covers 11,061,738 shares of its common stock. The supplement substitutes SILV Fund Ltd for Point72 Associates, LLC as a selling stockholder following a transfer of 876,340 shares.
The supplement amends the "Selling Stockholders" table to reflect the transfer and shows entities affiliated with Sirenia Capital Management LP beneficially own 11,604,590 shares ( 9.99%). The supplement reiterates the Prospectus terms and states the Nasdaq last sale price was $1.63 on April 28, 2026.
iBio, Inc. has filed a prospectus supplement to offer up to $100,000,000 of its common stock in an at-the-market offering through Jefferies LLC acting as sales agent.
Sales may occur from time to time under a Sales Agreement dated February 27, 2026, with commissions up to 3.0%. The prospectus states 34,543,561 shares outstanding as of February 24, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including potential acquisitions, licensing, or repurchases.
iBio, Inc. is registering up to 11,061,738 shares of common stock for resale by existing investors, including 1,408,481 already-issued shares and up to 9,653,257 shares underlying pre-funded warrants.
The company will not sell any shares in this offering and will not receive proceeds from stockholder resales, other than any cash paid if pre-funded warrants are exercised at $0.001 per share. These securities stem from a January 2026 private placement that generated approximately $26 million in gross proceeds at prices of $2.35 per share and $2.349 per pre-funded warrant.
iBio is a preclinical-stage biotechnology company using AI-driven antibody discovery to develop cardiometabolic and obesity therapies, with its IBIO-610 program expected to enter first-in-human trials in early 2027. Shares outstanding were 32,540,942 as of January 30, 2026, with 42,194,199 shares assuming full exercise of the pre-funded warrants.